Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 5 | 1 |
List of Figures | 5 | 1 |
Introduction | 6 | 1 |
Global Markets Direct Report Coverage | 6 | 1 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Overview | 7 | 1 |
Therapeutics Development | 8 | 4 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Products under Development by Stage of Development | 8 | 1 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Products under Development by Therapy Area | 9 | 1 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Products under Development by Indication | 10 | 2 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Pipeline Products Glance | 12 | 2 |
Late Stage Products | 12 | 1 |
Early Stage Products | 13 | 1 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Products under Development by Companies | 14 | 2 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Products under Development by Universities/Institutes | 16 | 2 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Therapeutics Assessment | 18 | 6 |
Assessment by Monotherapy/Combination Products | 18 | 1 |
Assessment by Mechanism of Action | 19 | 1 |
Assessment by Route of Administration | 20 | 2 |
Assessment by Molecule Type | 22 | 2 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Companies Involved in Therapeutics Development | 24 | 7 |
4SC AG | 24 | 1 |
Alnylam Pharmaceuticals, Inc. | 25 | 1 |
Array BioPharma Inc. | 26 | 1 |
Kyowa Hakko Kirin Co., Ltd. | 27 | 1 |
Merck &Co., Inc. | 28 | 1 |
Novartis AG | 29 | 1 |
Pfizer Inc. | 30 | 1 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Drug Profiles | 31 | 19 |
4SC-205 Drug Profile | 31 | 2 |
ALN-VSP Drug Profile | 33 | 3 |
BIND-267 Drug Profile | 36 | 1 |
BQS-481 Drug Profile | 37 | 1 |
filanesib Drug Profile | 38 | 4 |
LH-025 Drug Profile | 42 | 1 |
MK-8267 Drug Profile | 43 | 1 |
Small Molecule to Inhibit Kinesin Spindle Protein for Cancer Drug Profile | 44 | 2 |
Small Molecules to Inhibit Eg5 for Immunology and Oncology Drug Profile | 46 | 1 |
Small Molecules to Inhibit KSP for Oncology Drug Profile | 47 | 1 |
Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer Drug Profile | 48 | 1 |
SRI-35566 Drug Profile | 49 | 1 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Dormant Projects | 50 | 3 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Discontinued Products | 53 | 2 |
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Featured News &Press Releases | 55 | 17 |
Jun 03, 2015: 4SC Presents Final Results From Phase I AEGIS Trial As Well As Rationale For Daily Dosing Scheme Of 4SC-205 Cancer Compound At ASCO | 55 | 1 |
Dec 09, 2014: 4SC reports positive topline data from clinical Phase I trial with 4SC-205 in cancer patients using novel continuous dosing scheme | 56 | 2 |
Jul 29, 2013: Motor Protein Revs Up Cell Division | 58 | 1 |
Jun 17, 2013: Array BioPharma Announces Positive Interim Results From Combination Trial Of ARRY-520 With Kyprolis At 2013 European Hematology Association Congress | 58 | 2 |
Jun 06, 2013: Leukemia &Lymphoma Society Honors Ohi s Research | 60 | 1 |
Apr 04, 2013: Array BioPharma Presents Results From Two Ongoing ARRY-520 Clinical Trials In Multiple Myeloma At 2013 International Myeloma Workshop | 60 | 2 |
Jan 31, 2013: Tekmira Announces Publication Of Data On LNP Technology In Journal Cancer Discovery | 62 | 1 |
Jan 30, 2013: Alnylam And Collaborators Publish Results From Phase I Clinical Trial And Extension Study With ALN-VSP For Treatment Of Liver Cancer | 62 | 2 |
Dec 11, 2012: Array BioPharma Provides Updates On Clinical Data On ARRY-520 At 2012 American Society Of Hematology Meeting | 64 | 1 |
Dec 05, 2012: 4SC Reports Positive Data From Clinical Phase I Trial With 4SC-205 In Cancer Patients And Initiates Study Amendment | 65 | 1 |
Nov 05, 2012: Array BioPharma To Present Clinical Data On ARRY-520 At 2012 ASH Meeting | 66 | 2 |
Jun 04, 2012: Alnylam Presents Results From Phase I Extension Study Of ALN-VSP At ASCO 2012 Annual Meeting | 68 | 1 |
Mar 14, 2012: Tekmira Provides Update On Progress In USPTO Patent Interference Proceedings Related To Alnylam's ALN-VSP | 69 | 1 |
Dec 11, 2011: Array BioPharma's ARRY-520 Demonstrates Durable Single-Agent Activity In Patients With Advanced Multiple Myeloma | 70 | 1 |
Nov 29, 2011: Array Biopharma To Present Clinical Data On ARRY-520 At 2011 American Society Of Hematology Annual Meeting | 71 | 1 |
Appendix | 72 | 2 |
Methodology | 72 | 1 |
Coverage | 72 | 1 |
Secondary Research | 72 | 1 |
Primary Research | 72 | 1 |
Expert Panel Validation | 72 | 1 |
Contact Us | 72 | 1 |
Disclaimer | 73 | 1 |